Abstract
An overview of the biological activities of arsenic compounds containing more than one arsenic atom in their molecular structure is presented. This contribution covers the literature of the last 10–12 years concerning the in vitro and in vivo studies on arsenic species. They include inorganic oxides and sulfides, already employed for a long time in traditional Chinese medicine and currently investigated against hematological or solid malignancies, with arsenic trioxide clinically used in the treatment of acute promyelocytic leukemia. Chemical and biological aspects on the marine product arsenicin A, representing the first and only organic polyarsenical isolated from Nature, have also been reviewed, pointing out the characterization of its C3H6As4O3 molecular structure by experimental and theoretical vibrational spectroscopies, the potent antimicrobial activities, and the promising perspectives as an antitumor agent.
Keywords
- Acute Myeloid Leukemia
- Acute Promyelocytic Leukemia
- Arsenic Trioxide
- Arsenic Compound
- Acute Promyelocytic Leukemia Cell
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AML:
-
Acute myeloid leukemia
- APCI:
-
Atmospheric pressure chemical ionization
- APL:
-
Acute promyelocytic leukemia
- ATL:
-
Adult T-cell leukemia
- Bcl-xl:
-
B-cell lymphoma-extra large
- CML:
-
Chronic myelogenous leukemia
- DFT:
-
Density functional theory
- EI:
-
Electron impact
- FDA:
-
Food and drug administration
- Hh:
-
Hedgehog
- HTLV-I:
-
Human T-cell leukemia virus type I
- HPV:
-
Human papillomavirus
- IR:
-
Infrared
- JNK:
-
Jun N-terminal kinase
- MS:
-
Mass spectrometry
- NMR:
-
Nuclear magnetic resonance
- PML:
-
Promyelocytic leukemia
- RAR:
-
Retinoic acid receptor
- ROS:
-
Reactive oxygen species
- SAR:
-
Structure-activity relationship
- SDS:
-
Sodium dodecyl sulfate
- SUMO:
-
Small ubiquitin-like modifier
- SUV:
-
Small unilamellar vesicles
- TLC:
-
Thin layer chromatography
- UV:
-
Ultraviolet
References
Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, Namkoong SE, Lee IP, Kim CK, Seo JS, Sin JI, Kim YW (2004) Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 12:573–580
Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6:1–2. doi:10.1634/theoncologist.6-suppl_2-1
Arulmozhiraja S, Coote ML, Lu D, Salem G, Wild SB (2011) Origin of the unusual ultraviolet absorption of arsenicin A. J Phys Chem A 115:4530–4534. doi:10.1021/jp200956b
Au W-Y, Kwong Y-L (2008) Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 29:296–304. doi:10.1111/j.1745-7254.2008.00771.x
Balaz P, Sedlak J (2010) Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a mini review). Toxins 2:1568–1581. doi:10.3390/toxins2061568
Balaz P, Fabian M, Pastorek M, Cholujova D, Sedlak J (2009) Mechanochemical preparation and anticancer effect of realgar As4S4 nanoparticles. Mater Lett 63:1542–1544. doi:10.1016/j.matlet.2009.04.008 DOI:10.1016/j.matlet.2009.04.008#doilink
Binet F, Antoine F, Girard D (2009) Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin. Inflamm Allergy Drug Targets 8:21–27, http://dx.doi.org/10.2174/187152809787582516
Chang HS, Bae SM, Kim YW, Kwak SY, Min HJ, Bae IJ, Lee YJ, Shin JC, Kim CK, Ahn WS (2007) Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: relation to the apoptosis molecular pathway. Int J Oncol 30:1129–1135
Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY (2001) Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 38:26–36. doi:10.1016/S0037-1963(01)90003-4 DOI:10.1016/S0037-1963%2801%2990003-4#doilink
Chou W-C, Dang CV (2005) Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 12:1–6. doi:10.1097/01.moh.0000148552.93303.45
Chung WH, Sung BH, Kim SS, Rhim H, Kuh HJ (2009) Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol 34:1669–1679. doi:10.3892/ijo_00000298
Coe E, Schimmer AD (2008) Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma 49:1976–1981. doi:10.1080/10428190802353617
Cotton FA, Wilkinson G (1988) Advanced inorganic chemistry, vol 5. Wiley, New York, NY
Cui L, Newcombe C, Urgast DS, Raab A, Krupp EM, Feldmann J (2011) Assessing the toxicity of arsenic-bearing sulfide minerals with the bio-indicator Corophium volutator. Environ Chem 8:52–61. doi:10.1071/EN10044
Ellermann J, Lietz M, Merbach P, Thiele G, Zoubek G (1979) Chemie polyfunktioneller liganden,53Uber methyl-substituierte triarsa-trioxa-, triarsa-trithia-und triarsa-triaza-adamantane and űber den stark aufgeweiteten adamatan-käfig im schweel-derivat. Z Naturforsch 84b:975–982
Emadi A, Gore SD (2010) Arsenic trioxide—an old drug rediscovered. Blood Rev 24:191–199. doi:10.1016/j.blre.2010.04.001 DOI:10.1016/j.blre.2010.04.001#doilink
Evens AM, Tallman MS, Gartenhaus RB (2004) The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28:891–900
Francesconi KA, Kuehnelt D (2002) Arsenic compounds in the environment. In: Frankenberger WT Jr (ed) Environmental chemistry of arsenic. Dekker, New York, NY
Fu Z-C, Zhang B, Fu Z-J (2010) As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland. Med Hypotheses 75:490–491. doi:10.1016/j.mehy.2010.07.001 DOI:10.1016/j.mehy.2010.07.001#doilink
Gensini GF, Conti AA, Lippi D (2007) The contributions of Paul Ehrlich to infectious disease. J Infect 54:221–224. doi:10.1016/j.jinf.2004.05.022
Guella G, Mancini I, Mariotto G, Rossi B, Viliani G (2009) Vibrational analysis as a powerful tool in structure elucidation of polyarsenicals: a DFT-based investigation of arsenicin A. Phys Chem Chem Phys 11:2420–2427. doi:10.1039/b816729j
Hussein MA (2001) Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol 18:239–242, http://dx.doi.org/10.1385/MO:18:4:239
Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A, Arima T (2000) Arsenic trioxide and the growth of human T- cell leukemia virus type I infected T- cell lines. Leuk Lymphoma 37:649–655. doi:10.3109/10428190009058521
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigna DE, Teruya-Felstein J, Pandolfi PP (2008) PML targeting eradicated quiescent leukaemia-initiating cells. Nature 453:1072–1078. doi:10.1038/nature07016
Jing Y, Waxman S (2007) The design of selective and non-selective combination therapy for acute promyelocytic leukemia. Curr Top Microbiol Immunol 313:245–269. doi:10.1007/978-3-540-34594-7_13
Khan MAS, Oubrahim H, Stadtman ER (2004) Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci USA 101:11560–11565. doi:10.1073/pnas.0404101101
Kim J, Lee JJ, Kim J, Grdner D, Beachy PA (2007) Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 107:13432–13437. doi:10.1073/pnas.1006822107
Lin M, Wang Z, Zhang D (2007) Preparation of orpiment nanoparticles and their cytotoxic effect on cultured leukemia K562 cells. J Nanosci Nanotechnol 7:490–496. doi:10.1166/jnn.2007.145
Liu J, Lu Y, Wu Q, Goyer RA, Waalkes MP (2008) Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 326:363–368. doi:10.1124/jpet.108.139543
Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS (2005) The composition of Ehrlich’s Salvarsan: resolution of a century-old debate. Angew Chem Int Ed 44:941–944. doi:10.1002/anie.200461471
Lu D-P, Wang Q (2002) Current study of APL treatment in China. Int J Hematol 76:316–318
Lu D, Rae AD, Salem G, Weir ML, Willis AC, Wild SB (2010) Arsenicin A, a natural polyarsenical: synthesis and crystal structure. Organometallics 29:32–33. doi:10.1021/om90098q
Lu Y-F, Wu Q, Yan J-W, Shi J-Z, Liu J, Shi J-S (2011) Realgar, cinnabar and An-Gong-Niu-Huang Wan are much less chronically nephrotoxic than common arsenicals and mercurial. Exp Biol Med 236:233–239. doi:10.1016/j.cbi.2010.11.006
Mancini I, Guella G, Frostin M, Hnawia E, Laurent D, Debitus C, Pietra F (2006) On the first polyarsenic organic compound from nature: arsenicin A from the New Caledonian marine sponge Echinochalina bargibanti. Chem Eur J 12:8989–8994. doi:10.1002/chem.200600783
Mancini I, Defant A, Guella G (2007) Recent synthesis of marine natural products with antibacterial activities. AntiInfect Agents Med Chem 6:17–48. doi:10.1080/00397910802044249
Mann KK, Miller WH Jr (2004) Death by arsenic: implications of PML sumoylation. Cancer Cell 5:307–309, http://dx.doi.org/10.1016/S1535-6108(04)00089-3
Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893–3903, http://cancerres.aacrjournals.org/content/62/14/3893.full
Moe B, Chen B, Li XF, Le C (2010) Profiling the cytotoxicity of a novel polyarsenical in human carcinoma cell lines. Presented at the Faculty Research and Development Day Program, University of Alberta Canada, November 19th, 2010 Abstracts page17, http://www.pharm.ualberta.ca/~/media/University%20of%20Alberta/Faculties/Phacy%20and%20Pharmaceutical%20Sciences/Faculty%20Site/Research/Research%20Day/2010%20Research%20Day/BrochureResearch_Day_2010_3.pdf
Munir ZA, Street GB, Winters HF (1971) Mass-spectrometric and vapor pressure studies on the sublimation of realgar (As4S4). J Chem Phys 55:4520–4527
Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14:1333–1342. doi:10.1038/nm.1891
O’Day PA (2006) Chemistry and mineralogy of arsenic. Elements 2:77–83. doi:10.2113/gselements.2.2.77
Pagliai M, Bonazzi P, Bindi L, Muniz-Miranda M, Cardini G (2011) Structural and vibrational properties of arsenic sulfides: alacranite (As8S9). J Phys Chem A 115:4558–4562. doi:10.1021/jp201097k
Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, Hong SI, Eun CK, Zhang W, Rhee CH (2003a) Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol 22:1271–1276
Park IC, Park MJ, Woo SH, Lee HC, An S, Gwak HS, Lee SH, Hong SI, Bae IJ, Seo KM, Rhee CH (2003b) Tetraarsenic oxide induces apoptosis in U937 leukemic cells through a reactive oxygen species-dependent pathway. Int J Oncol 23:943–948
Park SG, Jung JJ, Won HJ, Kang MS, Seo SK, Choi IW, Eun CK, Ahn KJ, Park CW, Lee SW, Lew YS, Bae IJ, Choi IH (2009) Tetra-arsenic oxide (tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect. Cancer Lett 277:212–217. doi:10.1016/j.canlet.2008.12.012
Platanias LC, Robert H (2009) Biological responses to arsenic compounds. J Biol Chem 284:18583–18587. doi:10.1074/jbc.R900003200
Qi J, He P, Chen W, Wang H, Wang X, Zhang M (2010) Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res 34:1506–1516. doi:10.1016/j.leukres.2010.03.038
Ramadan D, Rancy PC, Nagarkar RP, Schneider JP, Thorpe C (2009) Arsenic (III) species inhibit oxidative protein folding in vitro. Biochemistry 48:424–432. doi:10.1021/bi801988x
Richardson PG, Mitsiades CS, Hideshima T, Anderson KC (2005) Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Hematol 18:619–634, http://dx.doi.org/10.1016/j.beha.2005.01.01
Sanchez Y, Amran D, de Blas E, Aller P (2010) Arsenic trioxide as an anti-tumour agent: mechanisms of action and strategies of sensitization. J Appl Biomed 8:199–208. doi:10.2478/v10136-009-0027-3
Shen Z-X, Shi Z-Z, Fang J, Gu B-W, Li J-M, Zhu Y-M, Shi J-Y, Zheng P-Z, Yan H, Liu Y-F, Chen Y, Shen Y, Wu W, Tang W, Waxman S, de Thé H, Wang Z-Y, Chen S-J, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101:5328–5335. doi:10.1073/pnas.0400053101
Shen XC, Jin T, Xie J, Liang H, Yan Y (2009) Studies on the biomimetic membrane interaction between liposome and realgar nanoparticles. Sci China B 52:1512–1518. doi:10.1007/s11426-009-0223-8
Singh P, Sharma R (1994) Effect of orpiment (As2S3) on cytochrome P 450, glutathione and lipid peroxide levels of rat liver. J Environ Pathol Toxicol Oncol 13:199–203
Singh P, Sharma R (1998) In vivo effects of orpiment administration on the lipid profile of rat lungs. Pollut Res 17:307–310
Singh P, Gregory MA, Sharma R, Kiran R (1999) Effects of orpiment (As2S3) toxicity on the kinetic and thermodynamic parameters of some brush-border membrane enzymes of rat intestine. Pollut Res 18:75–78
Tähtineen P, Saielli G, Mancini I, Bagno A (2008) Computational NMR spectroscopy of organoarsenicals and the natural polyarsenic compound arsenicin A. Chem Eur J 14:10445–10452. doi:10.1002/chem.200801272
Tang Y, Wang N, Zhang Y, Ye S, Ou W (2008) Effects of realgar on stress proteins, inflammatory mediators, and complement in brain tissue and serum of rats with inflammatory brain injury. Neural Regen Res 3:885–889
Wang ZY (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48:S72–S76. doi:10.1007/s002800100309
Wang J, Lin M, Zhang T, Yan Y, Ho PC, Xu QH, Loh KP (2008a) Arsenic(II) sulfide quantum dots prepared by a wet process from its bulk. J Am Chem Soc 130:11596–11597. doi:10.1021/ia804436w
Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z (2008b) Dissection of mechanisms of Chinese medicinal formula realgar-indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105:4826–4831. doi:10.1073/pnas.0712365105
Wang LW, Shi YL, Wang N, Gou BD, Zhang TL, Wang K (2009) Association of oxidative stress with realgar-induced differentiation in human leukemia HL-60 cells. Chemotherapy 55:460–467. doi:10.1159/000265528
Wang Y, Wu JIC, Li Q, von Ragué Schleyer P (2010) Why are some (CH)4X6 and (CH2)6X4 polyheteroadamantanes so stable? Org Lett 12:1320–1323. doi:10.1021/ol1002187
Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6:3–10. doi:10.1634/theoncologist.6-suppl_2-3
Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y (2009) Metabolic profiling studies on the toxicological effects of realgar in rats by 1H NMR spectroscopy. Toxicol Appl Pharmacol 234:314–325. doi:10.1016/j.taap.2008.11.010
Woo SH, Park MJ, An S, Lee HC, Jin HO, Lee SJ, Gwak HS, Park IC, Hong SI, Rhee CH (2005) Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells. J Cell Biochem 95:120–130. doi:10.1002/jcb.20329
Wu JZ, Ho PC (2006) Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci 29:35–44. doi:10.1016/j.ejps.2006.05.002
Wu J-Z, Ho PC (2009) Comparing the relative oxidative DNA damage caused by various arsenic species by quantifying urinary levels of 8-hydroxy-2′-deoxyguanosine with isotope-dilution liquid chromatography/mass spectrometry. Pharm Res 26:1525–1533. doi:10.1007/s11095-009-9865-7
Wu JZ, Shao YB, Liu JL, Chen G, Ho PC (2011) The medicinal use of realgar (As4S4) and its recent development as an anticancer agent. J Ethnopharmacol 135:595–602. doi:10.1016/j.jep.2011.03.071
Xu L, Zeng F, Ye H, Yang X, Xu H (2006) Anti-tumor activity of realgar nanoparticles and the distribution of arsenic (As) in tissues of tumor-transplanted mice. Zhongguo Xinyao Zazhi 15:1845–1848, CNKI:SUN:ZXYZ.0.2006-21-013
Yoo MH, Kim JT, Rhee CH, Park MJ, Bae IJ, Yi NY, Jeong MB, Jeong SM, Nam TC, Seo KM (2004) Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea. J Vet Med Sci 66:1091–1095. doi:10.1292/jvms.66.1091
Zhang C, Ling C (2003) Review of arsenic trioxide effect on solid cancer. Acad J Second Mil Med Univ 24:440–443, cnki:ISSN:0258-879X.0.2003-04-032
Zhang J, Wang JC, Han YH, Wang LF, Ji SP, Liu SX, Liu XP, Yao LB (2005) High expression of bcl-xL in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol 113:247–254. doi:10.1159/000084678
Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, Weng L, Zhang Y, Chen Q, Chen SJ, Chen Z (2009) A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci USA 106:3378–3383. doi:10.1073/pnas.0813142106
Zhang X, Xie Q, Wang X, Wang B, Li H (2010a) Biological extraction of realgar by and its in vitro and in vivo antitumor activities. Pharm Biol 48:40–47. doi:10.3109/13880200903029381
Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z (2010b) Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 328:240–243. doi:10.1126/science.1183424
Zhao W, Lu X, Yuan Y, Liu C, Yang B, Hong H, Wang G, Zeng F (2011) Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines. Int J Nanomedicine 6:1569–1577. doi:10.2147/IJN.S21373
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
To my father Giacomo (1926–2001), with love and gratefully.
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mancini, I., Defant, A. (2013). Bioactive Poly(Arsenic) Compounds. In: Müller, W., Wang, X., Schröder, H. (eds) Biomedical Inorganic Polymers. Progress in Molecular and Subcellular Biology, vol 54. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41004-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-41004-8_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-41003-1
Online ISBN: 978-3-642-41004-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)